[Treatment of Behçet's disease with adalimumab]

Med Clin (Barc). 2008 Oct 4;131(11):438-9. doi: 10.1157/13126223.
[Article in Spanish]
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adalimumab
  • Adult
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Behcet Syndrome / drug therapy*
  • Dermatologic Agents / administration & dosage
  • Dermatologic Agents / therapeutic use
  • Female
  • Humans
  • Injections, Subcutaneous
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / therapeutic use
  • Middle Aged
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • Adalimumab
  • Methotrexate